HLS THERAPEUTICS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.72 CAD | -7.00% |
|
-4.12% | -5.82% |
| Sales 2024 * | 58.06M 79.17M | Sales 2025 * | 64.72M 88.23M | Capitalization | 86.62M 118M |
|---|---|---|---|---|---|
| Net income 2024 * | -18M -24.54M | Net income 2025 * | -13M -17.72M | EV / Sales 2024 * | 1.49 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.34 x |
| P/E ratio 2024 * |
-4.56
x | P/E ratio 2025 * |
-6.48
x | Employees | 91 |
| Yield 2024 * |
5.36% | Yield 2025 * |
-
| Free-Float | 99.64% |
More Fundamentals
* Assessed data
More news
Latest transcript on HLS Therapeutics Inc.
More recommendations
More press releases
| 1 day | -7.00% | ||
| 1 week | -4.12% | ||
| Current month | -20.00% | ||
| 1 month | -20.00% | ||
| 3 months | -11.43% | ||
| 6 months | +6.59% | ||
| Current year | -5.82% |
1 week
3.57
4.00
1 month
3.574.80
Current year
3.525.48
1 year
3.347.12
3 years
3.3420.52
5 years
3.3425.92
10 years
3.3425.92
| Managers | Title | Age | Since |
|---|---|---|---|
Craig Millian
CEO | Chief Executive Officer | 56 | 23-04-30 |
John Hanna
DFI | Director of Finance/CFO | - | 23-06-21 |
Ryan Lennox
CMP | Compliance Officer | 43 | 18-05-06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Welborn
CHM | Chairman | 46 | 21-06-17 |
Laura Brege
BRD | Director/Board Member | 66 | 19-03-20 |
John Hanna
DFI | Director of Finance/CFO | - | 23-06-21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-30 | 3.72 | -7.00% | 8,406 |
| 24-05-29 | 4 | +6.38% | 5,548 |
| 24-05-28 | 3.76 | +1.62% | 901 |
| 24-05-27 | 3.7 | -4.64% | 701 |
| 24-05-23 | 3.88 | +0.78% | 6,500 |
Delayed Quote Toronto S.E., May 30, 2024 at 02:10 pm
More quotes
HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Insite, MyCare Psychiatry, PERSERIS, Trinomia and Vascepa. Its lead product is Clozaril, which is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Trinomia product related to the treatment of cardiovascular disease.
Sector
Pharmaceuticals
Calendar
2024-06-07
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.723
USD
Average target price
3.885
USD
Spread / Average Target
+42.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.82% | 86.62M | |
| +21.52% | 72.92B | |
| -2.79% | 23.8B | |
| +3.67% | 8.38B | |
| +8.19% | 8.33B | |
| -23.56% | 7.66B | |
| +15.87% | 5.13B | |
| -6.90% | 4.18B | |
| +2.47% | 4.06B | |
| +5.99% | 3.91B |
- Stock Market
- Equities
- HLS Stock
